Table 2 Relationship between financial status and QOL
Outcomes a | Overall (n = 123) | Financial status | Coefficient (95%CI)b | P | Coefficient (95% CI)c | P | ||
|---|---|---|---|---|---|---|---|---|
Low (n = 20) | Fair (n = 47) | Good (n = 56) | ||||||
QLQ-C30 | ||||||||
 Physical functioning | 80.0 ± 18.9 | 74.3 ± 16.4 | 75.7 ± 27.2 | 85.7 ± 20.7 | 4.4 (0.2 ~ 8.6)) | 0.038 | 9.1 (4.0 ~ 14.2) | 0.001 |
 Role functioning | 78.5 ± 26.3 | 71.7 ± 33.4 | 72.7 ± 27.2 | 85.7 ± 20.7 | 8.3 (2.0 ~ 14.6) | 0.010 | 12.7 (4.7 ~ 20.7) | 0.002 |
 Cognitive functioning | 78.6 ± 17.5 | 72.5 ± 22.5 | 75.5 ± 19.0 | 83.3 ± 12.7 | 5.9 (1.7 ~ 10.1) | 0.006 | 5.4 (1.3 ~ 9.5) | 0.005 |
 Emotional functioning | 72.4 ± 19.2 | 64.6 ± 21.3 | 68.4 ± 18.9 | 78.4 ± 17.0 | 7.6 (3.1 ~ 12.1) | 0.001 | 3.5 (0.5 ~ 6.5) | 0.028 |
 Social functioning | 64.2 ± 25.8 | 50.8 ± 29.4 | 55.7 ± 22.6 | 76.2 ± 21.8 | 14.3 (8.5 ~ 20.1) | <0.0001 | 13.4 (8.3 ~ 18.5) | 0.001 |
 Global health | 57.0 ± 18.1 | 57.5 ± 23.7 | 52.7 ± 22.5 | 59.4 ± 20.7 | NS |  | NS |  |
 Financial difficulties | 56.5 ± 21.9 | 93.3 ± 13.7 | 57.4 ± 28.4 | 27.4 ± 25.5 | −32.4 (−38.5 ~ −26.2) | <0.0001 | −30.1 (<0.0001) | |
 Fatigue | 37.2 ± 19.6 | 39.4 ± 22.1 | 40.2 ± 20.7 | 33.9 ± 17.4 | NS |  | −5.9 (−11.8 ~ −0.1) | 0.048 |
 Nausea and vomiting | 8.5 ± 14.8 | 8.3 ± 13.8 | 9.9 ± 17.3 | 7.4 ± 13.1 | NS | NS |  | |
 Pain | 21.8 ± 25.0 | 28.3 ± 27.1 | 24.1 ± 24.8 | 17.6 ± 24.1 | NS | −9.2 (−17.2 ~ −1.2) | 0.024 | |
 Dyspnea | 15.4 ± 21.9 | 16.7 ± 20.3 | 14.2 ± 18.1 | 16.1 ± 25.4 | NS | NS |  | |
 Insomnia | 32.2 ± 29.9 | 28.3 ± 27.1 | 34.0 ± 30.7 | 32.1 ± 30.5 | NS | NS | ||
 Appetite loss | 18.7 ± 24.1 | 18.3 ± 27.5 | 18.3 ± 20.6 | 19.0 ± 26.1 | NS | −8.8 (−15.6 ~ −2.0) | 0.011 | |
 Constipation | 19.0 ± 30.8 | 28.3 ± 34.7 | 27.7 ± 36.3 | 8.3 ± 19.3 | −12.0 (−19.2 ~ −4.7) | 0.001 | −12.3 (−21.8 ~ −2.9) | 0.011 |
 Diarrhea | 9.5 ± 17.3 | 5.0 ± 12.2 | 9.2 ± 16.6 | 11.3 ± 19.4 | NS |  | NS |  |
QLQ-OV28 | ||||||||
 Body image | 48.0 ± 24.9 | 60.0 ± 27.8 | 50.4 ± 22.9 | 41.7 ± 24.0 | −4.0 (−7.9 ~ −0.2) | 0.003 | −10.0 (−15.7 ~ −4.2) | 0.011 |
 Sexual functioning | 3.9 ± 9.6 | 6.67 ± 12.6 | 3.5 ± 10.4 | 3.2 ± 7.4 | NS |  | NS |  |
 Attitude toward disease/treatment | 60.5 ± 27.5 | 76.7 ± 23.6 | 66.7 ± 25.1 | 49.6 ± 26.6 | - 14.3 (−20.5 ~ −8.0) | <0.0001 | −12.9 (−1.2 ~ −6.3) | 0.002 |
 Abdominal symptoms | 19.7 ± 16.3 | 22.1 ± 20.7 | 23.1 ± 15.7 | 16.1 ± 14.5 | NS |  | NS |  |
 Neurological symptoms | 28.5 ± 22.5 | 30.6 ± 31.2 | 31.7 ± 22.5 | 25.0 ± 18.6 | NS | NS | ||
 Menopausal symptoms | 15.1 ± 17.5 | 16.7 ± 12.6 | 12.7 ± 14.8 | 14.6 ± 19.3 | NS | NS | ||
 Other side-effects | 15.5 ± 13.1 | 22.3 ± 19.6 | 16.3 ± 12.6 | 13.7 ± 11.8 | −4.0 (−7.3 ~ −0.6) | 0.020 | −5.3 (−8.8 ~ −1.8) | 0.018 |